Novavax Inc. (NASDAQ: NVAX) is currently generating a lot of buzz in the trading world due to a significant drop in its shares. The shares have suffered a 9.37% drop, now trading at $93.93 as of 11:43 EST. This marks a part of an overall negative trading session today. Previously, their last recorded close stood at $102.75, which is significantly below their 52-week high of $331.24. This ongoing trend may indicate emerging investor concerns or the beginning of profit-taking actions.
Novavax’s Groundbreaking COVID-19 Vaccine
Novavax has made headlines for their groundbreaking COVID-19 vaccine, NVX-CoV2373. Already on the market under various names such as Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine Adjuvanted, the company maintains its dedication to research. The focus doesn’t only remain on COVID-19 but extends to other health areas such as the development of influenza vaccines and innovative combinations between COVID-19 and influenza vaccinations.
Financial Forecast and Performance
Novavax reported an estimated trailing twelve-month earnings per share (EPS) of $14.89 and revealed an 11.5% sales growth during its most recent quarter. However, predictions for the next quarter show sales potentially decreasing by 51.8%. This decline could be attributed to either a saturated demand for COVID-19 vaccine sales or the impact of intensified competition.
Stock Market Trends and Volatility
While Novavax stock prices have taken a significant dive, the current worth starkly contrasts its 50-day moving average of $102.78 and the 200-day moving average of $219.09. This discrepancy implies potential downward trends. The shares’ intraday changes over the last week, month, and quarter registered average differences such as 1.72%, 1.01%, and 4.69% respectively. Notably, last week saw the highest degree of volatility at 7.10%.
Investor’s Dilemma
As common with biotech stocks, Novavax has witnessed significant fluctuations over the past year. The shares have fallen considerably below its 52-week high of $331.24 but remain well above its low of $76.61. Notwithstanding this significant decrease, the stock currently trades at $93.93, thus offering investors an entry point.
More news about Novavax (NVAX).
